- Optimising Treatment of HF
Optimising Treatment of HF
- CV Renal Metabolic
- Heart Failure
Course Published On:
Course Expiry Date:
Following recent changes to guidelines in light of the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes, this programme brings together a leading faculty to best inform of the latest clinical evidence and real-world application for optimising treatment strategies in heart failure.
Prof Martin Cowie (Imperial College London, UK), moderates the proceedings, that comprises a number of insightful presentations and a panel discussion, with contributions from Prof Giuseppe Rosano (St George's Hospitals NHS Trust, London, UK), Dr Javed Butler (University of Mississippi, US), and Dr Shelley Zieroth (University of Manitoba, Canada).
This programme is supported by an unrestricted educational grant from AstraZeneca, who has had no involvement in its organisation. Views and opinions expressed in the programme belong to the authors (faculty and delegates) and not necessarily to that of AstraZeneca.
In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Intended for healthcare professionals only.
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within the suggested timelines and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim credit participants must:
1. Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
2. Your results will be automatically saved and if a pass score is achieved, you may be eligible to claim credit for the activity and receive a certificate of completion.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
- Heart Failure Specialists
- General Cardiologists
- Allied Health Professionals
Upon completion of this activity, participants will be able to:
- Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
- Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
- Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
- Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases
|1||Introduction – Optimising Treatment of HF||Martin R Cowie (Royal Brompton Hospital, London, UK)|
|2||A Review of Recent SGLT2 Inhibitor Data||Giuseppe Rosano (University of London, London, UK)|
|3||New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?||Javed Butler (Jackson, Mississippi, US)|
|4||Existing HF-REF: Augmenting the SOC||Shelley Zieroth (University of Manitoba, Canada)|
|5||How Will SGLT2 Inhibition Provide the Greatest Impact on HF-REF?||Martin R Cowie (Royal Brompton Hospital, London, UK) Javed Butler (Jackson, Mississippi, US) Shelley Zieroth (University of Manitoba, Canada) Giuseppe Rosano (University of London, London, UK)|
Introduction – Optimising Treatment of HF
A Review of Recent SGLT2 Inhibitor Data
New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?
Existing HF-REF: Augmenting the SOC
How Will SGLT2 Inhibition Provide the Greatest Impact on HF-REF?
The programme ‘Optimising Treatment of HF’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
- Assess the current global burden of resistant hypertension
- Carry out appropriate assessments to identify resistant hypertension
- Identify patients most likely to benefit from RDN
- Recall the practical considerations for adopting RDN into routine practice
- Recall the latest data on RDN from recent clinical trials